Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation:
As of April 2026, the case for buying Pfizer (PFE) stock centers on its status as a "deep value" play with a high dividend yield, contrasted against significant mid-term revenue headwinds. Following its late-2025 financial guidance, which projected flat to slightly declining revenue for 2026, the stock has traded at a significant discount to its historical norms and the broader S&P 500. buy pfizer stock
: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 . Potential buyers must weigh the value proposition against